Capricor Therapeutics (CAPR) said Tuesday it has received the US Food and Drug Administration's acceptance for review of its biologics license application for full approval of deramiocel to treat Duchenne muscular dystrophy cardiomyopathy.
The regulator's decision was based on the company's current cardiac data from its phase 2 HOPE-2 and HOPE-2 open label extension studies, Capricor added.
The regulator set Aug. 31 as the Prescription Drug User Fee Act target action date without any potential review issues at the moment, the company said.
Capricor's stock rose nearly 12% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。